[CAS NO. 22254-24-6] Ipratropiumbromide

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [22254-24-6]

Catalog

AS093750

Brand

Arctom Scientific

CAS

22254-24-6

DESCRIPTION [22254-24-6]

Overview

MDL	MFCD00069291
Molecular Weight	412.36
Molecular Formula	C20H30BrNO3
SMILES	C[N+]1([C@H]2CC[C@H]1CC(OC(C(CO)C3=CC=CC=C3)=O)C2)C(C)C.[Br-]

For research use only. We do not sell to patients.

Summary

Ipratropium bromide (Sch 1000) is a muscarinic receptor antagonist, with IC ₅₀ s of 2.9 nM, 2 nM, and 1.7 nM for M1, M2, and M3 receptors, respectively. Ipratropium bromide relaxes smooth muscle, can be used in the research for COPD (chronic obstructive pulmonary disease) and asthma ^[1] ^[2] ^[3] ^[4] ^[5] .

IC50 & Target

2.9 nM (mAChR M1), 2 nM (mAChR M2), and 1.7 nM (mAChR M3) ^[3]

In Vitro

Ipratropium bromide (1 nM, 10 nM, 100 nM; 15 min) exerts its toxic effects via disruption of mitochondrial membrane potential ^[1] .
Ipratropium bromide (1 nM-1 μM; 4 h) increases infarct size in isolated perfused heart ischaemia/reperfusion experiments with a dose-responsive manner (EC 50=22.7 nM) ^[1] .
Ipratropium bromide (0.001 nM-0.1 mM; 2 h) inhibits adult rat cardiac myocyte growth after 4 h hypoxia treatment ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay ^[1]

Cell Line:	Adult Rat Cardiac Myocyte
Concentration:	0.001 nM-0.1 mM
Incubation Time:	2 h in dark; prior to 4 h hypoxia
Result:	Resulted cell viability in a dose-dependent manner, with the inhibition rate of 52.7% at 0.1 mM dose.

In Vivo

Ipratropium bromide (1.0 μg/kg; i.v.; single dose) enhances vagal nerve stimulation induing bronchoconstriction ^[2] .
Ipratropium bromide (0.04 mg/20 mL and 0.20 mg/20 mL; 30 min, rate=30 mL/30 min) can protect the lungs against the cadmium-induced acute neutrophilic inflammation by reducing the parenchyma inflammatory infiltration of neutrophils ^[4] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Guinea-pigs of the Dunkin Hartley strain ^[2] .
Dosage:	0.1-1 μg/kg
Administration:	Intravenous injection; single dose
Result:	Resulted little blocking effect on post-junctional muscarinic receptors at 0.3 μg/kg, and inhibited ACh-induced bronchoconstriction at 0.5 μg/kg.

Animal Model:	Male Sprague-Dawley rats (300-350 g) ^[4]
Dosage:	0.04 mg/20 mL and 0.20 mg/20 mL
Administration:	Inhalation; atomization rate of 30 mL/30 min; 30 min
Result:	Had no significant effects on any parameters recorded in healthy rats but exerted a protective effect against the inflammatory reaction elicited by cadmium.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT03480997	Pneuma Respiratory, Inc	COPD	December 27, 2016	Phase 1
NCT03136120	GlaxoSmithKline\|University College London Hospitals	Lung Diseases, Interstitial	November 21, 2017
NCT01136421	University of Monastir	COPD Exacerbation	January 2005	Phase 3
NCT00381589	Centre for Addiction and Mental Health	Hypersalivation	October 2006	Not Applicable
NCT02177344	Boehringer Ingelheim	Pulmonary Disease, Chronic Obstructive	August 1998	Phase 3
NCT01691079	University of California, San Francisco	Bronchospasm, Exercise-Induced	December 2012	Phase 4
NCT00588406	Northwell Health\|AstraZeneca\|Jacobi Medical Center\|Nassau University Medical Center	Asthma	September 2007	Phase 3
NCT04167280	University of Saskatchewan	Asthma	November 5, 2019	Phase 4
NCT00273962	Boehringer Ingelheim	Asthma	May 2002	Phase 4
NCT00605410	University of Saskatchewan\|Royal University Hospital Foundation	Asthma	January 2008	Phase 4
NCT00371527	Kaiser Permanente	Bronchitis	October 2002	Not Applicable
NCT02755714	Haukeland University Hospital	Exercise Induced Laryngeal Obstruction (EILO)	June 22, 2016	Phase 1\|Phase 2
NCT01696214	University of California, San Diego\|National Heart, Lung, and Blood Institute (NHLBI)	Asthma	October 2012	Phase 4
NCT00549120	GlaxoSmithKline	Pulmonary Disease, Chronic Obstructive	August 15, 2007	Phase 1
NCT03064113	Mylan Inc.\|Theravance Biopharma\|Viatris Inc.	Chronic Obstructive Pulmonary Disease, COPD	May 2011	Phase 2
NCT02182856	Boehringer Ingelheim	Pulmonary Disease, Chronic Obstructive	February 1998	Phase 4
NCT00928746	Boehringer Ingelheim	Pulmonary Disease, Chronic Obstructive	June 2009	Phase 3
NCT00274040	Boehringer Ingelheim	Pulmonary Disease, Chronic Obstructive	July 2002	Phase 3
NCT02207452	GlaxoSmithKline	Pulmonary Disease, Chronic Obstructive	August 5, 2010	Phase 1
NCT00807534	Laval University\|McGill University\|Boehringer Ingelheim	Chronic Obstructive Pulmonary Disease	October 2008	Not Applicable
NCT02235428	Boehringer Ingelheim	Asthma	September 1998	Phase 4
NCT02686086	Beaumont Hospital\|Aerogen	Chronic Obstructive Pulmonary Disease (COPD)	February 2016	Not Applicable
NCT02172404	Boehringer Ingelheim	Pulmonary Disease, Chronic Obstructive	October 2000	Phase 3
NCT01415518	AstraZeneca	Chronic Obstructive Pulmonary Disease (COPD)	September 1, 2011	Phase 4
NCT00239434	Boehringer Ingelheim	Pulmonary Disease, Chronic Obstructive	June 2003	Phase 3
NCT02584738	Hospital General Naval de Alta Especialidad - Escuela Medico Naval	Asthma	September 2015	Phase 4
NCT00388882	Boehringer Ingelheim	Pulmonary Disease, Chronic Obstructive	October 2006	Phase 4
NCT02172781	Boehringer Ingelheim	Healthy	January 2001	Phase 1
NCT02236182	Boehringer Ingelheim	Pulmonary Disease, Chronic Obstructive	July 1998	Phase 2
NCT01943552	Boehringer Ingelheim	Pulmonary Disease, Chronic Obstructive	October 2013	Phase 4
NCT00296946	University Health Network, Toronto\|Parkinson´s Disease Foundation	Parkinson´s Disease	November 2004	Phase 2
NCT02872597	University Hospitals Cleveland Medical Center	Status Asthmaticus	September 5, 2016	Phase 1
NCT04617015	State University of New York at Buffalo	Asthma\|Depression\|Childhood Asthma	September 9, 2016	Early Phase 1
NCT04315558	University of California, Los Angeles\|Theravance Biopharma\|Mylan Pharmaceuticals Inc	COPD\|Acute Respiratory Failure	November 1, 2020	Phase 2
NCT03747536	London Health Sciences Centre	Sialorrhea	January 1, 2019	Phase 2
NCT02236169	Boehringer Ingelheim	Pulmonary Disease, Chronic Obstructive	October 2000	Phase 2
NCT02182700	Boehringer Ingelheim	Asthma	July 1998	Phase 3
NCT03271905	Universidade Federal do Rio Grande do Norte	COPD\|Asthma	April 10, 2017	Not Applicable
NCT02172469	Boehringer Ingelheim	Pulmonary Disease, Chronic Obstructive	May 2001	Phase 3
NCT00911651	University Hospital, Antwerp\|GlaxoSmithKline	COPD	June 2008	Phase 4
NCT02177253	Boehringer Ingelheim	Pulmonary Disease, Chronic Obstructive	October 2002	Phase 3
NCT00393367	Children´s Hospital of Philadelphia	Asthma\|Acute Asthma\|Reactive Airway Exacerbation	December 2006	Phase 4
NCT00202176	Queen´s University	Chronic Obstructive Pulmonary Disease (COPD)	July 2005	Phase 4
NCT00498251	University Hospital, Geneva	Lung Injury, Acute\|Thoracotomy\|Anesthesia\|Intensive Care, Surgical\|Extravascular Lung Water	September 2004	Not Applicable
NCT00000568	National Heart, Lung, and Blood Institute (NHLBI)	Lung Diseases\|Lung Diseases, Obstructive\|Chronic Obstructive Pulmonary Disease	September 1984	Phase 3
NCT00521222	Columbia University	Asthma	June 2007	Not Applicable
NCT00904436	US Department of Veterans Affairs\|VA Office of Research and Development	Dyspnea\|Tetraplegia	December 1999	Not Applicable
NCT02542254	Verona Pharma plc	Chronic Obstructive Pulmonary Disease	October 2015	Phase 2
NCT01350128	Pearl Therapeutics, Inc.	Chronic Obstructive Pulmonary Disease	May 1, 2011	Phase 2
NCT03296579	University of British Columbia\|Post Graduate Institute of Medical Education and Research, Chandigarh	Asthma Acute\|Asthma in Children	June 2018	Not Applicable
NCT04184609	Ohio State University\|Nationwide Children´s Hospital	Asthma in Children\|Dyspnea; Asthmatic\|Obesity, Childhood	December 1, 2023	Phase 4
NCT00462540	Dey	Chronic Obstructive Pulmonary Disease	May 2007	Phase 3
NCT00180843	Imperial College London\|GlaxoSmithKline	Chronic Obstructive Pulmonary Disease	September 2005	Not Applicable
NCT02296047	Zhujiang Hospital\|Guangzhou Panyu Central Hospital	Chronic Obstructive Pulmonary Disease (COPD)	December 2014	Not Applicable
NCT02458482	Vanderbilt University Medical Center	Asthma	July 2015	Not Applicable
NCT04101500	Wuhan Union Hospital, China	Acute Exacerbation of Chronic Obstructive Pulmonary Disease	April 1, 2019	Phase 4
NCT01331694	GlaxoSmithKline	Pulmonary Disease, Chronic Obstructive	July 2009
NCT03738917	Jordi Gol i Gurina Foundation\|Spanish Clinical Research Network - SCReN	Acute Bronchitis	February 1, 2019	Phase 4
NCT01426009	Sunovion Respiratory Development Inc.	Chronic Obstructive Pulmonary Disease	August 2011	Phase 2
NCT02782052	Assistance Publique - Hôpitaux de Paris	Pulmonary Arterial Hypertension	July 2016	Phase 3
NCT00583778	MetroHealth Medical Center\|Sunovion	Asthma	August 2004	Not Applicable
NCT00117182	Pharmaxis	Lung Diseases, Obstructive	July 2005	Phase 2
NCT02260011	Boehringer Ingelheim	Pulmonary Disease, Chronic Obstructive	October 2000	Phase 2
NCT00274066	Boehringer Ingelheim	Pulmonary Disease, Chronic Obstructive	October 2002	Phase 3
NCT00480194	Nycomed	Common Cold	December 2006
NCT05550402	Hat Yai Medical Education Center	Asthma\|Airway Obstruction\|Airway Remodeling\|Parasympathetic Nervous System Diseases	January 1, 2023	Phase 3
NCT01691482	GlaxoSmithKline	Pulmonary Disease, Chronic Obstructive	July 23, 2012	Phase 4

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

H ₂ O : 100 mg/mL ( 242.51 mM ; Need ultrasonic)

DMSO : ≥ 35 mg/mL ( 84.88 mM )

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.4251 mL	12.1253 mL	24.2507 mL
5 mM	0.4850 mL	2.4251 mL	4.8501 mL
10 mM	0.2425 mL	1.2125 mL	2.4251 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: PBS

Solubility: 50 mg/mL (121.25 mM); Clear solution; Need ultrasonic
2.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (6.06 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (6.06 mM); Clear solution
4.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (6.06 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

8-Azoniabicyclo[3.2.1]octane, 3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-, bromide (1:1), (3-endo,8-syn)-

1αH,5αH-Tropanium, 3α-hydroxy-8-isopropyl-, bromide, (±)-tropate

8-Azoniabicyclo[3.2.1]octane, 3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-, bromide, (endo,syn)-(±)-

8-Isopropylatropinium bromide

8-Azoniabicyclo[3.2.1]octane, 3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-, bromide, (3-endo,8-syn)-

Sch 1000

Atrovent

Ipratropium bromide

N-Isopropylatropinium bromide

8-Azoniabicyclo[3.2.1]octane, 3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-, bromide, (endo,syn)-

Sch 100

N-Isopropylnoratropinium bromomethylate

Atrovent forte

Aerovent

Ipraxa